Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...
Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...
The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback